Rezolute, Inc. announced it has completed patient enrollment for its pivotal Phase 3 registrational study, upLIFT, evaluating its drug candidate ersodetug for the treatment of refractory hypoglycemia caused by tumor hyperinsulinism (HI). The company anticipates releasing topline results from the study in mid-December 2026.
Key Details
- Study: The open-label, single-arm Phase 3 upLIFT study is now fully enrolled with 16 participants.
- Drug & Indication: Ersodetug is being evaluated for its potential to treat severe hypoglycemia in patients with insulinoma or non-islet cell tumors.
- Timeline: Topline data from the study is expected to be announced in mid-December 2026.
- Primary Endpoint: The study's primary goal is to measure the proportion of participants who achieve at least a 50% reduction in their required intravenous glucose infusion rate from baseline during the 8-week treatment phase.